Ascendis Pharma A/SASNDNASDAQ
Loading
Year-over-year SG&A expense growth
| Period | Value |
|---|---|
| Q4 2025 | 19.26% |
| Q3 2025 | 5.65% |
| Q2 2025 | 10.52% |
| Q1 2025 | 21.41% |
| Q4 2024 | 15.64% |
| Q3 2024 | -8.32% |
| Q2 2024 | 11.27% |
| Q1 2024 | 4.39% |
| Q4 2023 | 2.34% |
| Q3 2023 | -11.05% |
| Q2 2023 | 5.62% |
| Q1 2023 | 17.66% |
| Q4 2022 | -6.79% |
| Q3 2022 | 7.22% |
| Q2 2022 | 19.33% |
| Q1 2022 | -1.83% |
| Q4 2021 | 22.96% |
| Q3 2021 | 11.14% |
| Q2 2021 | -5.11% |
| Q1 2021 | 82.35% |
| Q4 2020 | 16.57% |
| Q3 2020 | -15.78% |
| Q2 2020 | 16.13% |
| Q1 2020 | 4.91% |
| Q4 2019 | 70.77% |
| Q3 2019 | -8.76% |
| Q2 2019 | 5.02% |
| Q1 2019 | 24.64% |
| Q4 2018 | 23.20% |
| Q3 2018 | 30.04% |
| Q2 2018 | 12.10% |
| Q1 2018 | 14.10% |
| Q4 2017 | 43.87% |
| Q3 2017 | -12.10% |
| Q2 2017 | -2.83% |
| Q1 2017 | 1.19% |
| Q4 2016 | 24.42% |
| Q3 2016 | -1.05% |
| Q2 2016 | -8.22% |
| Q1 2016 | -16.20% |